NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $22.64 +0.87 (+4.00%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GH Research Stock (NASDAQ:GHRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GH Research alerts:Sign Up Key Stats Today's Range$21.81▼$23.8450-Day Range$13.03▼$22.5452-Week Range$10.66▼$24.66Volume241,964 shsAverage Volume318,194 shsMarket Capitalization$1.55 billionP/E RatioN/ADividend YieldN/APrice Target$40.38Consensus RatingModerate Buy Company Overview GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health. The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression. An additional preclinical candidate, GH002, is being developed for broader indications including anxiety, cognitive impairment and substance use disorders. GH Research employs a proprietary platform to optimize dosing, formulation delivery and real-time patient monitoring. Founded in 2017 by biotechnology entrepreneur Christian Angermayer, GH Research operates research facilities in Ireland and maintains collaborations with academic institutions and contract research organizations across Europe and North America. The executive leadership team combines expertise in psychiatry, neuroscience and drug development to advance the company’s pipeline. GH Research engages with regulatory authorities in multiple jurisdictions as it plans to initiate later-stage clinical trials and pursue strategic partnerships. The company’s goal is to bring innovative, psychedelic-derived therapeutics to patients worldwide who face debilitating psychiatric conditions.AI Generated. May Contain Errors. Read More GH Research Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreGHRS MarketRank™: GH Research scored higher than 58% of companies evaluated by MarketBeat, and ranked 386th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingGH Research has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGH Research has a consensus price target of $40.38, representing about 76.7% upside from its current price of $22.85.Amount of Analyst CoverageGH Research has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GH Research's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($1.46) to ($2.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -24.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -24.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GH Research's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.46% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 5.85.Change versus previous monthShort interest in GH Research has recently decreased by 0.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.65 News SentimentGH Research has a news sentiment score of -0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for GH Research this week, compared to 2 articles on an average week.MarketBeat Follows8 people have added GH Research to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GHRS Stock News HeadlinesGH Research: Rapid Onset And Short Action Change The Treatment ParadigmMay 20 at 5:01 AM | seekingalpha.comAssessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial PlansMay 16, 2026 | finance.yahoo.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 22 at 1:00 AM | Porter & Company (Ad)GH Research Launches $200 Million At-the-Market Share Offering With StifelMay 14, 2026 | tipranks.comGH Research Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comGH Research Raises $111 Million in Completed Share Offering to Fund Depression PipelineApril 30, 2026 | tipranks.comGH Research Announces Pricing of $117.5 Million Underwritten OfferingApril 29, 2026 | globenewswire.comGH Research: WH Decision On Psychedelics To Treat Depression Makes Bull CaseApril 20, 2026 | seekingalpha.comSee More Headlines GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $12.70 at the start of the year. Since then, GHRS shares have increased by 79.9% and is now trading at $22.85. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. When did GH Research IPO? GH Research (GHRS) raised $150 million in an IPO on Tuesday, June 22nd 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Who are GH Research's major shareholders? Top institutional investors of GH Research include Troluce Capital Advisors LLC (1.60%), Renaissance Technologies LLC (0.03%), Royal Bank of Canada and North Star Investment Management Corp.. How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GH Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Bristol Myers Squibb (BMY), Zoom Communications (ZM), Atai Beckley (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR). Company Calendar Last Earnings5/14/2026Today5/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 GHRS's financial health is in the Green zone, according to TradeSmith. GHRS has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GHRS CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees10Year Founded2018Price Target and Rating Average Price Target for GH Research$40.38 High Price Target$65.00 Low Price Target$32.00 Potential Upside/Downside+78.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-19.36% Return on Assets-18.73% Debt Debt-to-Equity RatioN/A Current Ratio34.13 Quick Ratio34.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.51 per share Price / Book5.02Miscellaneous Outstanding Shares68,610,000Free Float40,068,000Market Cap$1.55 billion OptionableOptionable Beta1.27 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GHRS) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
